Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 3/20 | 0.77 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.77 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.77 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.77 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83876 | 1.00 | GRIK1 (0.77) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL2502978 | 0.98 | GRIK1 (0.78) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL6898445 | 0.98 | GRIK1 (0.78) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL6032768 | 0.98 | GRIK1 (0.78) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL577908 | 0.98 | GRIK1 (0.78) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL1197864 | 0.98 | GRIK1 (0.78) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL8034530 | 0.98 | GRIK1 (0.78) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL3798142 | 0.98 | GRIK1 (0.78) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL17785976 | 0.98 | GRIK1 (0.78) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL4843975 | 0.95 | GRIK1 (0.75) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142781-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | MAGNESIUM DIAGNOSTICS INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-8129545-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110281923-A1 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | MAGNESIUM DIAGNOSTICS INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-7982048-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110021633-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | MAGNESIUM DIAGNOSTICS, INC. | 2011-01-27 | — | — | US | disclosed |
| US-7795450-B2 | Antagonist of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100048711-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-7619097-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20090030080-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-7211667-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-20070010535-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological atates | MAGNESIUM DIAGNOSTICS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142781-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | PLPBP, ECE1, MCU | GRIK1 537/4885GRIK2 836/4885SLC1A2 145/4885 |
| US-20070010535-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological atates | ECE1, GLS, ECE2 | GRIK1 297/4885GRIK2 568/4885SLC1A2 91/4885 |
| US-20100048711-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | PLPBP, ECE1, MCU | GRIK1 537/4885GRIK2 836/4885SLC1A2 145/4885 |
| US-20090030080-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | PLPBP, ECE1, MCU | GRIK1 537/4885GRIK2 836/4885SLC1A2 145/4885 |
| US-20110021633-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | PLPBP, ECE1, MCU | GRIK1 537/4885GRIK2 836/4885SLC1A2 145/4885 |
| US-20110281923-A1 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | PLPBP, ECE1, MCU | GRIK1 537/4885GRIK2 836/4885SLC1A2 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.